reports
Dormakaba Holding AG: 1 director
A director at Dormakaba Holding AG bought 1,250 shares at 669.359CHF and the significance rating of the trade was 100/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years...
- Emmanuel Matot
- Emmanuel Matot
- Delphine Brault
- Quentin Borie
Dormakaba : Confirmation of medium-term guidance at the CMD
>Medium-term guidance confirmed - The new CEO, Till Reuter, yesterday held his first CMD and set out his strategic roadmap to continue the group’s recovery. The group boasts a world no. 3 position (7% share) in a market with solid entry barriers. We note that 60% of the market is aftermarket business and the group is looking to draw on its installed base (CHF 20bn added over the last 15 years), with services accounting for 15% of its revenues. More client-centric...
- Delphine Brault
- Quentin Borie
Dormakaba : Confirmation des objectifs de moyen terme lors du CMD
>Les objectifs de moyen terme sont confirmés - Le nouveau CEO, Till Reuter, a tenu hier son 1er CMD et présenté sa feuille de route stratégique pour poursuivre le redressement du groupe. Ce dernier détient une position de n°3 mondial (7% de parts de marché) sur un marché qui dispose de solides barrières à l’entrée. Rappelons que 60% du marché est de l’after market et le groupe entend s’appuyer sur sa base installée (20 MdCHF ajoutés sur les 15 dernières années), les s...
- Martial Descoutures
- Oussema Denguir
MC LVMH MOET HENNESSY LOUIS VUITTON SE
DKSH DKSH HOLDING AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
F3C SFC ENERGY AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
GREEN GREENYARD NV
MONC MONCLER SPA
EDR EDREAMS ODIGEO SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
VOS VOSSLOH AG
EFIC1 EUROPEAN FINTECH IPO CO 1 BV
AELIS AELIS FARMA SA
NCH2 THYSSENKRUPP NUCERA AG & CO.
SPG SPRINGER NATURE AG & CO. KGAA
- Martial Descoutures
- Oussema Denguir
MC LVMH MOET HENNESSY LOUIS VUITTON SE
DKSH DKSH HOLDING AG
UHR SWATCH GROUP LTD. BEARER
RMS HERMES INTERNATIONAL SCA
F3C SFC ENERGY AG
EL ESSILORLUXOTTICA SA
BRBY BURBERRY GROUP PLC
KER KERING SA
01913 PRADA S.P.A.
GREEN GREENYARD NV
MONC MONCLER SPA
EDR EDREAMS ODIGEO SA
BC BRUNELLO CUCINELLI S.P.A.
CFR COMPAGNIE FINANCIERE RICHEMONT SA
SLR SOLARIA ENERGIA Y MEDIO AMBIENTE S.A.
VOS VOSSLOH AG
EFIC1 EUROPEAN FINTECH IPO CO 1 BV
AELIS AELIS FARMA SA
NCH2 THYSSENKRUPP NUCERA AG & CO.
SPG SPRINGER NATURE AG & CO. KGAA
- Martial Descoutures
- Oussema Denguir
Aelis Farma : Initial evidence of efficacy in cognitive disorders
>Positive results in phase I/II of AEF0217 in Down’s syndrome - Last night we learned of the initial positive results of Aelis’ phase I/II trial evaluating AEF0217 in Down's syndrome (trisomy 21). The trial had two objectives: first, to demonstrate safety for patients, and second, to provide an initial proof of concept and efficacy. There were no notable side-effects. Adverse events were similar in the placebo and AEF0217 groups. Most of the adverse events observ...
- Oscar Haffen Lamm
Aelis: AEF0217 showed encouraging efficacy signals in the phase 1/2 in...
Aelis reported positive results for the phase 1/2 trial with AEF0217 in Down Syndrom patients, meeting the primary (safety), secondary (PK) and exploratory endpoints (efficacy). We view the safety data consistent with the one observed in prior phase 1 study in healthy candidates, which further vali
- Martial Descoutures
- Oussema Denguir
Aelis Farma : Une première preuve d’efficacité dans les troubles cogni...
>Résultats positifs dans la phase I/II d’AEF0217 dans le syndrome de Down - Nous apprenions hier soir les premiers résultats positifs de sa phase I/II évaluant AEF0217 dans le syndrome de Down (trisomie 21). Cet essai avait deux objectifs : tout d’abord démontrer une sécurité d’emploi pour les patients mais aussi une première preuve de concept et d’efficacité. Nous pouvons souligner qu’aucun effet secondaire notable n’a été relevé. Les effets indésirables étaient...
Aelis Farma annonce les résultats positifs de son étude clinique de ph...
BORDEAUX, France--(BUSINESS WIRE)-- Regulatory News: Deux visioconférences se tiendront demain, mardi 19 novembre 2024 en français à 10h00 CET et en anglais à 16h00 CET / 10h00 ET. Pour participer, enregistrez-vous ici : Aelis Farma (ISIN : FR0014007ZB4 – Mnémonique : AELIS, éligible PEA-PME), société biopharmaceutique au stade clinique spécialisée dans le développement de traitements pour les maladies du cerveau et périphériques impliquant le récepteur CB1 du système endocannabinoïde, annonce aujourd’hui les résultats positifs d’une étude de phase 1/2 avec AEF02171 chez de jeunes ...
dormakaba ernennt Christian Baur zum President Key & Wall Solutions an...
dormakaba Holding AG / Schlagwort(e): Personalie dormakaba ernennt Christian Baur zum President Key & Wall Solutions and OEM sowie zum Chief Transformation Officer 18.11.2024 / 18:00 CET/CEST Rümlang, 18. November 2024 – dormakaba hat mit Wirkung zum 1. Januar 2025 Christian Baur als President Key & Wall Solutions and OEM sowie als Chief Transformation Officer in die Geschäftsleitung der dormakaba Gruppe berufen. Als President Key & Wall Solutions and OEM folgt er auf Stefano Zocca, der sich nach über 13-jähriger Tätigkeit entschlossen hat, das Unternehmen zu verlassen und s...
Christian Baur appointed President Key & Wall Solutions and OEM and Ch...
dormakaba Holding AG / Key word(s): Personnel Christian Baur appointed President Key & Wall Solutions and OEM and Chief Transformation Officer 18.11.2024 / 18:00 CET/CEST Rümlang, 18 November 2024 – dormakaba announces that Christian Baur will join dormakaba Group’s Executive Committee as President Key & Wall Solutions and OEM as well as Chief Transformation Officer effective 1 January 2025. As President Key & Wall Solutions and OEM, he follows Stefano Zocca who after over 13 years of tenure has decided to leave the company to pursue new professional opportunities. Additiona...
- Jerôme Bodin
ALLIX WALLIX GROUP SA
APAML APERAM SA
DEC JCDECAUX SA
NRG NRJ GROUP SA
GOE GROUPE GORGE SA
ALTA ALTAREA SCA
BAMNB KONINKLIJKE BAM GROEP NV
BON BONDUELLE SCA
ADV ADVA AG OPTICAL NETWORKING
AALB AALBERTS N.V.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
SIFG SIF HOLDING NV
FNTN FREENET AG
ALFEN ALFEN NV
COP COMPUGROUP MEDICAL SE & CO. KGAA
TCH TECHNICOLOR SA
ECMPA EUROCOMMERCIAL PROPERTIES NV
IVG IVECO GROUP
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
BRE BREMBO S.P.A.
- Jerôme Bodin
ALLIX WALLIX GROUP SA
APAML APERAM SA
DEC JCDECAUX SA
NRG NRJ GROUP SA
LNA LNA SANTE SA
GOE GROUPE GORGE SA
ALTA ALTAREA SCA
BAMNB KONINKLIJKE BAM GROEP NV
BON BONDUELLE SCA
ADV ADVA AG OPTICAL NETWORKING
AALB AALBERTS N.V.
ROVI LABORATORIOS FARMACEUTICOS ROVI S.A.
VGP VGP NV
SIFG SIF HOLDING NV
FNTN FREENET AG
ALFEN ALFEN NV
COP COMPUGROUP MEDICAL SE & CO. KGAA
TCH TECHNICOLOR SA
ECMPA EUROCOMMERCIAL PROPERTIES NV
IVG IVECO GROUP
FLE PEGASUS ENTREPRENEURIAL ACQUISITION CO EURO BV
BRE BREMBO S.P.A.
- Thijs Berkelder
SIF : Expansion project and backlog on track for EBITDA boost in 2025 ...
>Q3 stronger than expected as production downtime well under control - Throughput in 24Q3 was 42kt, down from 50kt a year ago, well ahead of our downbeat forecast of 24kt (for caution reasons we assumed longer downtime of the factory for the expansion project), implying YTD throughput is 128kt (144kt in 9M23).The expansion project is on schedule, now with two out of three production lines mechanically complete and now in the commissioning and operational start-up...
- ING Helpdesk
Benelux Morning Notes
Aperam: 3Q24 results solid, reassuring 4Q24 guidance. bpost: 3Q24 results and FY24 outlook in line. Eurocommercial Properties: Solid results, guidance confirmed at the top of the range. Euronext: A €300m buyback is next. IMCD: In line 3Q24. SBM Offshore: Prosperity taken out. Sif Group: Line 2 now also reporting for duty
- ING Helpdesk
Benelux Morning Notes
Ageas: More bidders for ESURE UK ASR: Completion of KNAB sale, starting extra SBB D'Ieteren: Holding financing more costly, 2024 guidance (excluding financing) reassures Ebusco: Released from obligation to deliver 76 buses PostNL: 3Q24 below, FY24 outlook down, mail weak, parcels stronger; CEO steps down Sif Group: Preview - getting ready for 2025 Staffing: US temp volume weaker in October, Aug/Sep revised down, NFP jobs miss
Generalversammlung stimmt allen Anträgen zu
dormakaba Holding AG / Schlagwort(e): Generalversammlung Generalversammlung stimmt allen Anträgen zu 10.10.2024 / 18:30 CET/CEST Rümlang, 10. Oktober 2024 – An der heutigen ordentlichen Generalversammlung der dormakaba Holding AG haben die Aktionärinnen und Aktionäre alle Anträge des Verwaltungsrats genehmigt. 241 Aktionärinnen und Aktionäre nahmen persönlich teil. Insgesamt waren 2 883 737 stimmberechtigte Namensaktien vertreten, was 68.6% des im Handelsregister eingetragenen Aktienkapitals entspricht. Die Aktionärinnen und Aktionäre stimmten allen Anträgen des Verwaltungs...
Annual General Meeting approves all proposals
dormakaba Holding AG / Key word(s): AGMEGM Annual General Meeting approves all proposals 10.10.2024 / 18:30 CET/CEST Rümlang, 10 October 2024 – At today's Annual General Meeting of dormakaba Holding AG, shareholders approved all the proposals of the Board of Directors. 241 shareholders attended in person. A total of 2 883 737 registered shares with voting rights were represented, corresponding to 68.6% of the share capital recorded in the commercial register. The shareholders approved all proposals of the Board of Directors with a large majority, including the payment of a ...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.